A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Matching Placebo to UstekinumabDrug: Matching Placebo to JNJ-77242113
- Registration Number
- NCT06934226
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 675
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 1: JNJ 77242113 JNJ-77242113 Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. Arm 1: JNJ 77242113 Matching Placebo to Ustekinumab Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. Arm 2: Placebo JNJ-77242113 Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. Arm 2: Placebo Matching Placebo to JNJ-77242113 Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. Arm 2: Placebo Matching Placebo to Ustekinumab Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. Arm 3: Ustekinumab JNJ-77242113 Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. Arm 3: Ustekinumab Matching Placebo to JNJ-77242113 Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. Arm 3: Ustekinumab Ustekinumab Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.
- Primary Outcome Measures
Name Time Method JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16 Week 16 IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 Week 16 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
- Secondary Outcome Measures
Name Time Method JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16 Week 16 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16 Week 16 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16 Week 16 IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28 Week 28 IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28 Week 28 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28 Week 28 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16 Week 16 PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16 Week 16 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to Week 108 An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product \& is medically important.
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16 Week 16 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16 Baseline up to Week 16 DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16 Week 16 DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16 Baseline up to Week 16 BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28 Week 28 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28 Baseline up to Week 28 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28 Baseline up to Week 28 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28 Week 28 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28 Week 28 PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28 Baseline up to Week 28 DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28 Week 28 DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16 Baseline up to Week 16 BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16 Week 16 IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16 Week 16 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16 Week 16 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (115)
Hosp. Cuf Descobertas
🇵🇹Lisboa, Portugal
Ulssa Hosp. Santo Antonio
🇵🇹Porto, Portugal
Hosp. Univ. San Cecilio
🇪🇸Granada, Spain
Rosenpark Research GmbH
🇩🇪Darmstadt, Germany
Cahaba Research Inc
🇺🇸Birmingham, Alabama, United States
Integrative Skin Science and Research
🇺🇸Sacramento, California, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Indiana Clinical Trial Center
🇺🇸Plainfield, Indiana, United States
Wilmington Dermatology Center
🇺🇸Wilmington, North Carolina, United States
Advanced Research Experts PLLC
🇺🇸Nashville, Tennessee, United States
Center for Clinical Studies
🇺🇸Webster, Texas, United States
Progressive Clinical Research
🇺🇸San Antonio, Texas, United States
Texas Dermatology and Laser Specialists
🇺🇸San Antonio, Texas, United States
Frontier Derm Partners CRO, LLC
🇺🇸Mill Creek, Washington, United States
Mindout Research
🇦🇷Buenos Aires, Argentina
CIPREC
🇦🇷Caba, Argentina
Instituto de Investigaciones Medicas Tucuman
🇦🇷Tucuman, Argentina
The Alfred Hospital
🇦🇺Melbourne, Australia
Innovaderm Research Inc.
🇨🇦Montreal, Quebec, Canada
Southern California Dermatology
🇺🇸Santa Ana, California, United States
Driven Research LLC
🇺🇸Coral Gables, Florida, United States
Bioclinical Research Alliance Inc.
🇺🇸Miami, Florida, United States
Forcare Clinical Research Inc
🇺🇸Tampa, Florida, United States
Hamilton Research LLC
🇺🇸Alpharetta, Georgia, United States
Equity Medical
🇺🇸Bowling Green, Kentucky, United States
MediSearch Clinical Trials
🇺🇸Saint Joseph, Missouri, United States
Metro Boston Clinical Partners
🇺🇸Brighton, Massachusetts, United States
The Derm Institute of West Michigan
🇺🇸Caledonia, Michigan, United States
Cleaver Dermatology
🇺🇸Kirksville, Missouri, United States
Arlington Research Center, Inc.
🇺🇸Arlington, Texas, United States
Kalo Clinical Research
🇺🇸West Valley City, Utah, United States
Halitus Instituto Medico S.A. - Dermatologia y Estetica
🇦🇷Caba, Argentina
Mautalen Salud e Investigacion
🇦🇷Caba, Argentina
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Somerset Skin Centre
🇺🇸Troy, Michigan, United States
Modern Research Associates PLLC
🇺🇸Dallas, Texas, United States
Instituto de Neumonologia y Dermatologia
🇦🇷Buenos Aires, Argentina
Investigaciones Medicas IMOBA SRL
🇦🇷Caba, Argentina
Instituto De Especialidades De La Salud SRL
🇦🇷Rosario, Argentina
Premier Specialists
🇦🇺Kogarah, Australia
ISHI dermatology
🇦🇺Mitcham, Australia
AZ St. Lucas
🇧🇪Gent, Belgium
Ghent University Hospital
🇧🇪Ghent, Belgium
Dermatrials Research
🇨🇦Hamilton, Ontario, Canada
Hamzavi Dermatology
🇺🇸Fort Gratiot, Michigan, United States
Minnesota Clinical Study Center
🇺🇸New Brighton, Minnesota, United States
Sadick Research Group
🇺🇸New York, New York, United States
Oregon Dermatology and Research Center
🇺🇸Portland, Oregon, United States
Clinical Research Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Health Concepts
🇺🇸Rapid City, South Dakota, United States
Cornerstone Dermatology
🇦🇺Coorparoo, Australia
The Centre de recherche Saint-Louis
🇨🇦Quebec, Canada
Optima Research
🇺🇸Boardman, Ohio, United States
Oregon Medical Research Center
🇺🇸Portland, Oregon, United States
Royal Melbourne Hospital
🇦🇺Melbourne, Australia
CCA Medical Research Corporation
🇨🇦Ajax, Ontario, Canada
Odense University Hospital
🇩🇰Odense, Denmark
Sjællands University hospital
🇩🇰Roskilde, Denmark
Universitaetsklinikum Schleswig Holstein Campus Kiel
🇩🇪Kiel, Germany
Universitaetsklinikum Muenster
🇩🇪Muenster, Germany
Uno Medical Trials Ltd.
ðŸ‡ðŸ‡ºBudapest, Hungary
Debreceni Egyetem Klinikai Kozpont
ðŸ‡ðŸ‡ºDebrecen, Hungary
Care Clinic Sp z o o
🇵🇱Katowice, Poland
Centrum Medyczne Oporow
🇵🇱Wroclaw, Poland
Grupo Dermatologico Y Estetico Pedro Jaen
🇪🇸Madrid, Spain
Hosp. Univ. de La Princesa
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. de Manises
🇪🇸Manises, Spain
Hosp. Clinico Univ. de Santiago
🇪🇸Santiago Compostela, Spain
Gentofte Hospital
🇩🇰Hellerup, Denmark
Bispebjerg Hospital
🇩🇰Kobenhavn NV, Denmark
Fachklinik Bad Bentheim
🇩🇪Bad Bentheim, Germany
ISA - Interdisciplinary Study Association GmbH
🇩🇪Berlin, Germany
Studienzentrum an der Hase GbR
🇩🇪Bramsche, Germany
Derma-Study-Center Friedrichshafen GmbH
🇩🇪Friedrichshafen, Germany
Derma-B Kft
ðŸ‡ðŸ‡ºDebrecen, Hungary
Gyongyosi Bugat Pal Korhaz
ðŸ‡ðŸ‡ºGyongyos, Hungary
Bacs-kiskun Megyei Korhaz
ðŸ‡ðŸ‡ºKecskemet, Hungary
Medmare Egeszsegugyi Es Szolgaltato Bt.
ðŸ‡ðŸ‡ºVeszprem, Hungary
Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
🇵🇱Krakow, Poland
Gemeinschaftspraxis Dres. Quist
🇩🇪Mainz, Germany
Hautarztpraxis
🇩🇪Witten, Germany
Obudai Egeszsegugyi Centrum Kft
ðŸ‡ðŸ‡ºBudapest, Hungary
Somogy Varmegyei Kaposi Mor Oktato Korhaz
ðŸ‡ðŸ‡ºKaposvar, Hungary
Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
🇵🇱Elblag, Poland
Studienzentrum Dr Schwarz Germany
🇩🇪Langenau, Germany
Dermatologie Mahlow
🇩🇪Mahlow, Germany
Synexus Magyarorszag Kft
ðŸ‡ðŸ‡ºGyula, Hungary
Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
ðŸ‡ðŸ‡ºHodmezovasarhely, Hungary
Dermed Centrum Medyczne Sp z o o
🇵🇱Lodz, Poland
Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
🇵🇱Warszawa, Poland
Klinika Ambroziak Dermatologia
🇵🇱Warszawa, Poland
Allergo-Derm Bakos Kft.
ðŸ‡ðŸ‡ºSzolnok, Hungary
Osteo-Medic s.c A. Racewicz, J Supronik
🇵🇱Bialystok, Poland
Specderm Poznanska sp j
🇵🇱Bialystok, Poland
Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
🇵🇹Braga, Portugal
Unidade Local De Saude Da Regiao De Leiria Epe
🇵🇹Leiria, Portugal
Hosp. Gral. Univ. Dr. Balmis
🇪🇸Alicante, Spain
Etyka Osrodek Badan Klinicznych Tomasz Pesta S K A
🇵🇱Olsztyn, Poland
SOLUMED Centrum Medyczne
🇵🇱Poznan, Poland
WroMedica
🇵🇱Wroclaw, Poland
Hosp. Clinic de Barcelona
🇪🇸Barcelona, Spain
Hosp. Virgen Macarena
🇪🇸Sevilla, Spain
Hosp. Ntra. Sra. de Valme
🇪🇸Sevilla, Spain
Hosp. Univ. I Politecni La Fe
🇪🇸Valencia, Spain
Hosp. de La Marina Baixa
🇪🇸Villajoyosa, Spain
Hosp. Clinico Univ. Lozano Blesa
🇪🇸Zaragoza, Spain
Hosp. Univ. Miguel Servet
🇪🇸Zaragoza, Spain
London North West University Healthcare NHS Trust
🇬🇧Harrow, United Kingdom
The Queen Elizabeth Hospital NHS Foundation Trust
🇬🇧Kings Lynn, United Kingdom
Guys and St Thomas NHS Foundation Trust
🇬🇧London, United Kingdom
Royal Berkshire Hospital
🇬🇧Reading, United Kingdom
Salford Royal Hospital
🇬🇧Salford, United Kingdom
University Hospital Southampton
🇬🇧Southampton, United Kingdom
Mid Yorkshire NHS Trust
🇬🇧Wakefield, United Kingdom